<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.1d3" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0309160</article-id>
<article-id pub-id-type="publisher-id">PONE-D-24-13515</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Hormones</subject><subj-group><subject>Androgens</subject><subj-group><subject>Testosterone</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Hormones</subject><subj-group><subject>Lipid hormones</subject><subj-group><subject>Testosterone</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Epidemiology</subject><subj-group><subject>Pandemics</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>People and places</subject><subj-group><subject>Population groupings</subject><subj-group><subject>Age groups</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Pharmaceutics</subject><subj-group><subject>Therapeutic drug monitoring</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>People and places</subject><subj-group><subject>Geographical locations</subject><subj-group><subject>North America</subject><subj-group><subject>United States</subject><subj-group><subject>Texas</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Medical conditions</subject><subj-group><subject>Infectious diseases</subject><subj-group><subject>Viral diseases</subject><subj-group><subject>COVID 19</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>People and places</subject><subj-group><subject>Geographical locations</subject><subj-group><subject>North America</subject><subj-group><subject>United States</subject><subj-group><subject>Iowa</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Urology</subject><subj-group><subject>Hypogonadism</subject></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Cross-sectional analysis of national testosterone prescribing through prescription drug monitoring programs, 2018–2022</article-title>
<alt-title alt-title-type="running-head">Analysis of national testosterone prescribing trends, 2018–2022</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" equal-contrib="yes" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5336-3778</contrib-id>
<name name-style="western">
<surname>Selinger</surname>
<given-names>Scott</given-names>
</name>
<role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role>
<role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
<role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
<name name-style="western">
<surname>Thallapureddy</surname>
<given-names>Aneesh</given-names>
</name>
<role content-type="http://credit.niso.org/contributor-roles/software/">Software</role>
<role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Department of Internal Medicine, Division of General Internal Medicine, University of Texas at Austin Dell Medical School, Austin, Texas, United States of America</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>University of Texas at Austin Dell Medical School, Austin, Texas, United States of America</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>de Silva</surname>
<given-names>Appuwawadu Mestri Nipun Lakshitha</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>General Sir John Kotelawala Defence University Faculty of Medicine, SRI LANKA</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">scott.selinger@austin.utexas.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>28</day>
<month>8</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>19</volume>
<issue>8</issue>
<elocation-id>e0309160</elocation-id>
<history>
<date date-type="received">
<day>7</day>
<month>4</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>7</day>
<month>8</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-year>2024</copyright-year>
<copyright-holder>Selinger, Thallapureddy</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0309160"/>
<abstract>
<sec id="sec001">
<title>Background</title>
<p>For two decades preceding the COVID-19 pandemic, testosterone therapy (TT) became more prevalent in the US. Given the forced shift in practice patterns and healthcare accessibility during the pandemic, it was unclear how TT utilization would change.</p>
</sec>
<sec id="sec002">
<title>Objective</title>
<p>To assess the change in testosterone prescriptions nationally.</p>
</sec>
<sec id="sec003">
<title>Design</title>
<p>Cross-sectional study.</p>
</sec>
<sec id="sec004">
<title>Data sources</title>
<p>State prescription drug monitoring program data between 2018 and 2022.</p>
</sec>
<sec id="sec005">
<title>Participants</title>
<p>All individuals filling testosterone prescriptions in participating states.</p>
</sec>
<sec id="sec006">
<title>Measurements</title>
<p>Unique people filling testosterone prescriptions annually, demographic information on gender and age as available.</p>
</sec>
<sec id="sec007">
<title>Results</title>
<p>In 2022 there was a 27% relative increase of subjects treated with TT (+439,659 cases compared with 2018). The increase was more evident in the pandemic period with a rise in prevalence most notable for people 45–54 (114,114 people, 35% increase) and 35–44 (97,263 people, 58% increase). All regions except the Midwest increased the total population treated, led by the South (52%) followed by the West (28%) and Northeast (23%). Available data indicated men accounted for most patients treated in all age groups except under 24 years.</p>
</sec>
<sec id="sec008">
<title>Limitations</title>
<p>Study population limited to those in participating states with no diagnostic information and limited demographics available.</p>
</sec>
<sec id="sec009">
<title>Conclusion</title>
<p>Between 2018 and 2022, and primarily after the start of the pandemic in 2020, nationally there was a substantial increase in the number of people using TT. The largest increases occurred in a younger demographic, primarily men, than have previously been reported or studied. These results echo other findings showing increased use of controlled substances during the pandemic period and warrant further study regarding the factors behind this rise.</p>
</sec>
</abstract>
<funding-group>
<funding-statement>The author(s) received no specific funding for this work.</funding-statement>
</funding-group>
<counts>
<fig-count count="5"/>
<table-count count="3"/>
<page-count count="11"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>Data cannot be shared publicly because all of the data was obtained through separate data use agreements with individual states participating in this study. Some of those agreements obligate us to destroy the data after publication, others prohibit the data from being shared without permission from the governing body, and some data does not have that restriction. All of the data obtained was freely available on individual request from the following institutional points of contact, and data may be shared by these institutions on reasonable request and with the completion of a Data Use Agreement. Requests may be directed to the institutions listed in the Supplementary file titled 'Contact information for participating states.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec010" sec-type="intro">
<title>Introduction</title>
<p>Testosterone therapy (TT) prescribing has experienced significant growth since 2000 [<xref ref-type="bibr" rid="pone.0309160.ref001">1</xref>]. The number of new and total users grew for the first decade of this millennium before decreasing in 2013 when research signaled an increased risk of myocardial infarction and stroke associated with testosterone use [<xref ref-type="bibr" rid="pone.0309160.ref002">2</xref>]. Direct marketing of TT towards men has increased [<xref ref-type="bibr" rid="pone.0309160.ref003">3</xref>] and our earlier analysis of the Texas Prescription Drug Monitoring Program (PDMP) revealed a recent and substantial rise in the population-level incidence of TT [<xref ref-type="bibr" rid="pone.0309160.ref004">4</xref>], strongly driven by new treatment of a younger population than has typically been included in prior research. The goal of this study was to assess the changes in prescribing patterns nationally to see if this reflected a larger trend.</p>
</sec>
<sec id="sec011" sec-type="materials|methods">
<title>Materials &amp; methods</title>
<p>This cross-sectional study was exempted from review by The University of Texas at Austin Dell Medical School institutional review board. Patient informed consent was waived owing to the use of deidentified and aggregated data. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines.</p>
<p>We sought prescription data through PDMPs for fifty states and the District of Columbia. With their cataloging of controlled substance prescriptions filled at state pharmacies, data was requested containing demographic characteristics of all people filling prescriptions for controlled substances at outpatient pharmacies from all fifty states and the District of Colombia. Data was requested and analyzed between April and December 2023.</p>
<p>To assemble the cohort, state PDMPs or their supervising authority were contacted individually for participation. Due to administrative and regulatory hurdles varying by state, our data request refocused from deidentified prescription records to aggregated numbers of unique patients treated with testosterone annually, broken down for six patient age groups (&lt;24, 25–34, 35–44, 45–54, 55–64, and 65+). National Drug Codes and drug names were used to identify testosterone prescriptions. Diagnosis codes and treatment indications were not available and gender information was not consistently available.</p>
<p>To account for population growth and interstate migration, population estimates were obtained from the United States Census between 2018 and 2022 to evaluate the population percentage receiving a prescription for TT. Prevalence rates for the populations for our defined age groups were also calculated. To consider changes during the COVID-19 pandemic, we compared a linear forecast of patients treated with TT based on 2018–2020 data with the actual 2021–2022 values and visualized the difference in prevalence percentage using Microsoft Excel for Microsoft 365 MSO (Version 2310).</p>
</sec>
<sec id="sec012" sec-type="results">
<title>Results</title>
<p>Of the 51 entities contacted, 25 were included for analysis. Reasons for non-participation were legislative prohibition of data-sharing, lack of data collection during the defined period and lack of response to multiple data requests, delineated by state in <xref ref-type="table" rid="pone.0309160.t001">Table 1</xref>. Participating entities controlling PDMP data are listed in <xref ref-type="table" rid="pone.0309160.t002">Table 2</xref>. Most states performed the analyses and shared the aggregated data while Arkansas, Iowa, Kentucky, New Jersey, Texas, and Wisconsin provided access to deidentified data for our analysis. Due to data classification incongruent with our age stratification, Wisconsin was excluded from the final analysis.</p>
<table-wrap id="pone.0309160.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0309160.t001</object-id>
<label>Table 1</label> <caption><title>Reasons provided by PDMP for non-participation in data-sharing.</title></caption>
<alternatives>
<graphic id="pone.0309160.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0309160.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center">Legislative Prohibition</th>
<th align="center">Requested Data Unavailable</th>
<th align="center">Did Not Respond</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center">California</td>
<td align="center">Alaska</td>
<td align="center">Indiana</td>
</tr>
<tr>
<td align="center">Delaware</td>
<td align="center">Hawaii</td>
<td align="center">Mississippi</td>
</tr>
<tr>
<td align="center">District of Colombia</td>
<td align="center">Illinois</td>
<td align="center">North Carolina</td>
</tr>
<tr>
<td align="center">Florida</td>
<td align="center">Maine</td>
<td align="center">South Dakota</td>
</tr>
<tr>
<td align="center">Michigan</td>
<td align="center">Missouri</td>
<td align="center">Vermont</td>
</tr>
<tr>
<td align="center">Nebraska</td>
<td align="center">Montana</td>
<td align="center">West Virginia</td>
</tr>
<tr>
<td align="center">Nevada</td>
<td align="center">New Mexico</td>
<td align="center"/>
</tr>
<tr>
<td align="center">New York</td>
<td align="center">Wyoming</td>
<td align="center"/>
</tr>
<tr>
<td align="center"/>
<td align="center">North Dakota</td>
<td align="center"/>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
<table-wrap id="pone.0309160.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0309160.t002</object-id>
<label>Table 2</label> <caption><title>Participating Entities providing PMP data.</title></caption>
<alternatives>
<graphic id="pone.0309160.t002g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0309160.t002" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
</colgroup>
<tbody>
<tr>
<td align="left">Alabama Department of Public Health</td>
</tr>
<tr>
<td align="left">Arizona Board of Pharmacy</td>
</tr>
<tr>
<td align="left">Arkansas Department of Health</td>
</tr>
<tr>
<td align="left">Colorado State Board of Pharmacy</td>
</tr>
<tr>
<td align="left">Georgia Department of Public Health</td>
</tr>
<tr>
<td align="left">Idaho Division of Occupational &amp; Professional Licenses</td>
</tr>
<tr>
<td align="left">Iowa Department of Health &amp; Human Services</td>
</tr>
<tr>
<td align="left">Kansas Board of Pharmacy</td>
</tr>
<tr>
<td align="left">Kentucky Cabinet for Health &amp; Family Services, OIG</td>
</tr>
<tr>
<td align="left">Louisiana Board of Pharmacy</td>
</tr>
<tr>
<td align="left">Maryland Department of Health</td>
</tr>
<tr>
<td align="left">Massachusetts Department of Public Health</td>
</tr>
<tr>
<td align="left">New Hampshire Department of Health and Human Services</td>
</tr>
<tr>
<td align="left">New Jersey Division of Consumer Affairs</td>
</tr>
<tr>
<td align="left">Ohio Board of Pharmacy</td>
</tr>
<tr>
<td align="left">Oklahoma Bureau of Narcotics and Dangerous Drugs Control</td>
</tr>
<tr>
<td align="left">Oregon Health Authority</td>
</tr>
<tr>
<td align="left">Pennsylvania Department of Health</td>
</tr>
<tr>
<td align="left">Rhode Island Department of Health</td>
</tr>
<tr>
<td align="left">South Carolina Department of Health &amp; Environmental Control</td>
</tr>
<tr>
<td align="left">Tennessee Department of Health</td>
</tr>
<tr>
<td align="left">Texas State Board of Pharmacy</td>
</tr>
<tr>
<td align="left">Division of Occupational and Professional Licensing (DOPL)</td>
</tr>
<tr>
<td align="left">Utah Controlled Substance Database</td>
</tr>
<tr>
<td align="left">Virginia Department of Health Professions</td>
</tr>
<tr>
<td align="left">Washington State Department of Health</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
<p>Within the study period, the number of people in the total sample treated with testosterone annually increased 27% from 1,216,982 to 1,656,641 in 2022. Considered regionally, this increase was largest in the South at 52% (AL, AR, GA, KY, LA, OK, SC, TN, TX, VA), followed by the West at 28% (AZ, CO, OR, UT, WA) and Northeast at 23% (MD, MA, NH, NJ, PA, RI), while a decrease of 7% was seen in the Midwest (IA, KS, OH). Considering population changes, the percentage of the study population filling a testosterone prescription increased 30% from 0.76% to 0.98%. There was similarly varied regional growth seen in <xref ref-type="fig" rid="pone.0309160.g001">Fig 1</xref> with TT prevalence decreasing in the Midwest (-24%) and rising in the Northeast (20%), West (24%) and South (47%).</p>
<fig id="pone.0309160.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0309160.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Percentage of regional population filling prescription for testosterone by year.</title>
<p>Green—Midwest (IA, KS, OH), Blue—Northeast (MD, MA, NH, NJ, PA, RI), Red—South (AL, AR, GA, KY, LA, OK, SC, TN, TX, VA), Yellow—West (AZ, CO, OR, UT, WA).</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0309160.g001" xlink:type="simple"/>
</fig>
<p>Age group analysis (<xref ref-type="table" rid="pone.0309160.t003">Table 3</xref>) shows increases in TT prevalence seen in those 24 and under (120%), 25–34 (86%), 35–44 (45%), 45–54 (35%), 55–64 (17%) and 65 and older (12%). The largest absolute increases were seen in the middle age groups, 45–54 (114,114) and 35–44 (97,263). Compared to the overall study period, the increase in TT patients between 2020–2022 accounted for most of the growth in all age groups (<xref ref-type="fig" rid="pone.0309160.g002">Fig 2</xref>)– 24 and under (51%), 25–34 (69%), 35–44 (74%), 45–54 (83%), 55–64 (93%), 65 and older (85%). The interstate differences in actual vs expected growth by population percentage in the study period are shown in <xref ref-type="fig" rid="pone.0309160.g003">Fig 3</xref>. Calculated incidence rates per 100,000 of the total population (<xref ref-type="fig" rid="pone.0309160.g004">Fig 4</xref>) showed the largest increase in the 45–54 group, followed by the 35–44 and 55–64 groups, with near convergence of the 35–44 and &gt;65 groups.</p>
<fig id="pone.0309160.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0309160.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Increase in population treated with testosterone in study period by age group.</title>
<p>Blue portion represents increase in prevalence from 2018–2020, Orange portion represents 2020–2022 period.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0309160.g002" xlink:type="simple"/>
</fig>
<fig id="pone.0309160.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0309160.g003</object-id>
<label>Fig 3</label>
<caption>
<title>2021–22 growth of population receiving TT compared to 2018–2020 forecasting.</title>
<p>Representation of the difference in predicted vs actual prevalence of TT. Prevalence of TT forecasted through 2022 based on prescription data from 2018–2020. Blue states represent difference in prevalence consistent with prior trends, with lower and higher prevalence reflected in gradations of red and green, respectively. Iowa was excluded due to absence of data from 2018.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0309160.g003" xlink:type="simple"/>
</fig>
<fig id="pone.0309160.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0309160.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Population prevalence of testosterone therapy over time.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0309160.g004" xlink:type="simple"/>
</fig>
<table-wrap id="pone.0309160.t003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0309160.t003</object-id>
<label>Table 3</label> <caption><title>Patients treated (population percentage) with testosterone therapy.</title></caption>
<alternatives>
<graphic id="pone.0309160.t003g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0309160.t003" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left"/>
<th align="left"/>
<th align="center">Midwest</th>
<th align="center">Northeast</th>
<th align="center">South</th>
<th align="center">West</th>
<th align="center">Total</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" rowspan="5">24 and under</td>
<td align="center">2018</td>
<td align="center">887 (0.04)</td>
<td align="center">7839 (0.07)</td>
<td align="center">10940 (0.04)</td>
<td align="center">8190 (0.09)</td>
<td align="center">27856 (0.05)</td>
</tr>
<tr>
<td align="center">2019</td>
<td align="center">1754 (0.05)</td>
<td align="center">9378 (0.08)</td>
<td align="center">13962 (0.05)</td>
<td align="center">10258 (0.11)</td>
<td align="center">35352 (0.07)</td>
</tr>
<tr>
<td align="center">2020</td>
<td align="center">1937 (0.06)</td>
<td align="center">10511 (0.09)</td>
<td align="center">18902 (0.06)</td>
<td align="center">12044 (0.13)</td>
<td align="center">43394 (0.08)</td>
</tr>
<tr>
<td align="center">2021</td>
<td align="center">2554 (0.08)</td>
<td align="center">12926 (0.11)</td>
<td align="center">18623 (0.06)</td>
<td align="center">14803 (0.15)</td>
<td align="center">48906 (0.09)</td>
</tr>
<tr>
<td align="center">2022</td>
<td align="center">3105 (0.09)</td>
<td align="center">14822 (0.13)</td>
<td align="center">24119 (0.08)</td>
<td align="center">17654 (0.18)</td>
<td align="center">59700 (0.11)</td>
</tr>
<tr>
<td align="center" rowspan="5">25–34</td>
<td align="center">2018</td>
<td align="center">5857 (0.31)</td>
<td align="center">9360 (0.19)</td>
<td align="center">26126 (0.23)</td>
<td align="center">15351 (0.36)</td>
<td align="center">56694 (0.25)</td>
</tr>
<tr>
<td align="center">2019</td>
<td align="center">7767 (0.33)</td>
<td align="center">10390 (0.21)</td>
<td align="center">29347 (0.26)</td>
<td align="center">17019 (0.39)</td>
<td align="center">64523 (0.28)</td>
</tr>
<tr>
<td align="center">2020</td>
<td align="center">6588 (0.29)</td>
<td align="center">12040 (0.24)</td>
<td align="center">34502 (0.31)</td>
<td align="center">19468 (0.45)</td>
<td align="center">72598 (0.32)</td>
</tr>
<tr>
<td align="center">2021</td>
<td align="center">7884 (0.34)</td>
<td align="center">15217 (0.3)</td>
<td align="center">40367 (0.36)</td>
<td align="center">23509 (0.54)</td>
<td align="center">86977 (0.38)</td>
</tr>
<tr>
<td align="center">2022</td>
<td align="center">8794 (0.38)</td>
<td align="center">16980 (0.34)</td>
<td align="center">54803 (0.48)</td>
<td align="center">28199 (0.64)</td>
<td align="center">108776 (0.47)</td>
</tr>
<tr>
<td align="center" rowspan="5">35–44</td>
<td align="center">2018</td>
<td align="center">16061 (0.92)</td>
<td align="center">18288 (0.41)</td>
<td align="center">92989 (0.9)</td>
<td align="center">40882 (1.06)</td>
<td align="center">168220 (0.82)</td>
</tr>
<tr>
<td align="center">2019</td>
<td align="center">19103 (0.89)</td>
<td align="center">18860 (0.41)</td>
<td align="center">101343 (0.97)</td>
<td align="center">43167 (1.09)</td>
<td align="center">182473 (0.87)</td>
</tr>
<tr>
<td align="center">2020</td>
<td align="center">15015 (0.68)</td>
<td align="center">21055 (0.44)</td>
<td align="center">110965 (1.04)</td>
<td align="center">46289 (1.15)</td>
<td align="center">193324 (0.89)</td>
</tr>
<tr>
<td align="center">2021</td>
<td align="center">16519 (0.74)</td>
<td align="center">26061 (0.54)</td>
<td align="center">126231 (1.17)</td>
<td align="center">51943 (1.26)</td>
<td align="center">220754 (1.01)</td>
</tr>
<tr>
<td align="center">2022</td>
<td align="center">16548 (0.74)</td>
<td align="center">27923 (0.57)</td>
<td align="center">161129 (1.47)</td>
<td align="center">59883 (1.44)</td>
<td align="center">265483 (1.19)</td>
</tr>
<tr>
<td align="center" rowspan="5">45–54</td>
<td align="center">2018</td>
<td align="center">21614 (2.72)</td>
<td align="center">39865 (0.81)</td>
<td align="center">188463 (1.68)</td>
<td align="center">74046 (2.1)</td>
<td align="center">323988 (1.58)</td>
</tr>
<tr>
<td align="center">2019</td>
<td align="center">26163 (2.29)</td>
<td align="center">38916 (0.81)</td>
<td align="center">197383 (1.78)</td>
<td align="center">76544 (2.18)</td>
<td align="center">339006 (1.65)</td>
</tr>
<tr>
<td align="center">2020</td>
<td align="center">24868 (2.17)</td>
<td align="center">40238 (0.83)</td>
<td align="center">198824 (1.79)</td>
<td align="center">78946 (2.23)</td>
<td align="center">342876 (1.66)</td>
</tr>
<tr>
<td align="center">2021</td>
<td align="center">27303 (2.4)</td>
<td align="center">45604 (0.96)</td>
<td align="center">217302 (1.96)</td>
<td align="center">85226 (2.39)</td>
<td align="center">375435 (1.83)</td>
</tr>
<tr>
<td align="center">2022</td>
<td align="center">29627 (2.59)</td>
<td align="center">45861 (0.98)</td>
<td align="center">268142 (2.42)</td>
<td align="center">94472 (2.63)</td>
<td align="center">438102 (2.14)</td>
</tr>
<tr>
<td align="center" rowspan="5">55–64</td>
<td align="center">2018</td>
<td align="center">26216 (3.03)</td>
<td align="center">50860 (0.99)</td>
<td align="center">199012 (1.8)</td>
<td align="center">89411 (2.49)</td>
<td align="center">365499 (1.77)</td>
</tr>
<tr>
<td align="center">2019</td>
<td align="center">30720 (2.4)</td>
<td align="center">50283 (0.98)</td>
<td align="center">206092(1.85)</td>
<td align="center">91066 (2.52)</td>
<td align="center">378161 (1.79)</td>
</tr>
<tr>
<td align="center">2020</td>
<td align="center">26367 (2.07)</td>
<td align="center">51853 (0.98)</td>
<td align="center">201628 (1.8)</td>
<td align="center">90820 (2.52)</td>
<td align="center">370688 (1.74)</td>
</tr>
<tr>
<td align="center">2021</td>
<td align="center">27139 (2.16)</td>
<td align="center">57006 (1.09)</td>
<td align="center">215677 (1.93)</td>
<td align="center">93471 (2.61)</td>
<td align="center">393293 (1.85)</td>
</tr>
<tr>
<td align="center">2022</td>
<td align="center">28393 (2.31)</td>
<td align="center">54447 (1.05)</td>
<td align="center">255840 (2.3)</td>
<td align="center">97323 (2.75)</td>
<td align="center">436003 (2.07)</td>
</tr>
<tr>
<td align="center" rowspan="5">65 and older</td>
<td align="center">2018</td>
<td align="center">27878 (1.14)</td>
<td align="center">40195 (0.64)</td>
<td align="center">136474 (1.16)</td>
<td align="center">70868 (1.54)</td>
<td align="center">275415 (1.1)</td>
</tr>
<tr>
<td align="center">2019</td>
<td align="center">33063 (1.08)</td>
<td align="center">40733 (0.63)</td>
<td align="center">143271 (1.18)</td>
<td align="center">73749 (1.54)</td>
<td align="center">290816 (1.1)</td>
</tr>
<tr>
<td align="center">2020</td>
<td align="center">25035 (0.8)</td>
<td align="center">42058 (0.64)</td>
<td align="center">143044 (1.16)</td>
<td align="center">76370 (1.58)</td>
<td align="center">286507 (1.06)</td>
</tr>
<tr>
<td align="center">2021</td>
<td align="center">24230 (0.76)</td>
<td align="center">47528 (0.7)</td>
<td align="center">158144 (1.25)</td>
<td align="center">80432 (1.61)</td>
<td align="center">310334 (1.14)</td>
</tr>
<tr>
<td align="center">2022</td>
<td align="center">24981 (0.77)</td>
<td align="center">44786 (0.64)</td>
<td align="center">194632 (1.49)</td>
<td align="center">84178 (1.63)</td>
<td align="center">348577 (1.23)</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
<p>Analysis of gender-identifying information was only available for Arizona, Arkansas, Iowa, Kentucky, and New Jersey. Between 2018–2022, in all age groups, the male percentage of TT patients decreased, notably in the under 24 group where females became the majority, likely reflecting a rise in gender-affirming care. For all other age groups, men accounted for at least two-thirds of the TT population (<xref ref-type="fig" rid="pone.0309160.g005">Fig 5</xref>).</p>
<fig id="pone.0309160.g005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0309160.g005</object-id>
<label>Fig 5</label>
<caption>
<title>Percentage of testosterone prescriptions filled by men by age group over time.</title>
<p>Data only available for AZ, AR, IA, KY, NJ.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0309160.g005" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec013" sec-type="conclusions">
<title>Discussion</title>
<p>In this cross-sectional study, there was a substantial increase in the number of people receiving TT nationally between 2018–2022, most of which occurred after the onset of the COVID-19 pandemic in 2020. The demographics driving this increase were younger men, more prominently in the South and West than the Northeast, with diminishing usage in the Midwest, consistent with prior geographic differences in prescribing patterns [<xref ref-type="bibr" rid="pone.0309160.ref001">1</xref>, <xref ref-type="bibr" rid="pone.0309160.ref005">5</xref>]. By 2022, TT prevalence increased in the 35–44 group to match those 65 and older.</p>
<p>Some of our findings are consistent with prior trends in the US. Between 2016–2019, claim numbers for TT increased nearly 50%, largely driven by an increasing proportion of prescribers from primary care, internal medicine, and family practice physicians as well as nurse practitioners and physician’s assistants, far more than from urologists and endocrinologists [<xref ref-type="bibr" rid="pone.0309160.ref006">6</xref>]. The prevalence of hypogonadism based on claims data had increased nearly 600% between 2008–2017 with similar variations in distribution geographically to our study, but with growth driven more by those older than 45 [<xref ref-type="bibr" rid="pone.0309160.ref007">7</xref>]. In the past, TT has been administered much more readily [<xref ref-type="bibr" rid="pone.0309160.ref008">8</xref>] and with more liberal interpretations for treatment initiation in the U.S [<xref ref-type="bibr" rid="pone.0309160.ref009">9</xref>]. than most other countries who track this data, though we could find no more recent TT analyses of prescribing patterns internationally during the COVID-19 pandemic.</p>
<p>The onset of the pandemic, and the societal shifts and socioeconomic pressures around it, promoted or deepened common somatic symptoms such as fatigue, poor sleep, depression, anxiety, and unintentional weight gain, all of which overlap with the non-specific symptoms of hypogonadism [<xref ref-type="bibr" rid="pone.0309160.ref010">10</xref>–<xref ref-type="bibr" rid="pone.0309160.ref012">12</xref>]. The peri-pandemic period saw increased use of mood-altering controlled substances such as opioids [<xref ref-type="bibr" rid="pone.0309160.ref013">13</xref>], stimulants and non-stimulant ADHD treatments, anti-depressants, benzodiazepines [<xref ref-type="bibr" rid="pone.0309160.ref014">14</xref>] and z-hypnotics [<xref ref-type="bibr" rid="pone.0309160.ref015">15</xref>]. Already underdiagnosed and undertreated based on the gender discrepancy between diagnoses and suicide rates [<xref ref-type="bibr" rid="pone.0309160.ref016">16</xref>], depression in men worsened during the pandemic [<xref ref-type="bibr" rid="pone.0309160.ref017">17</xref>]. TT has shown a positive, albeit modest, effect on mood and depressive symptoms in older men with hypogonadism [<xref ref-type="bibr" rid="pone.0309160.ref018">18</xref>], so perhaps a similar pattern could explain patients seeking this therapy for symptom alleviation.</p>
<p>The magnitude of change in new patients treated may stem from guideline-discordant care offered by direct-to-consumer platforms [<xref ref-type="bibr" rid="pone.0309160.ref019">19</xref>] given their ease of access. Our prior study performed on data solely from Texas showed that most growth in the TT population came from high-volume prescribers treating over one thousand patients per year, five hundred times greater than the average prescriber, and that the average patient filled two or fewer prescriptions over a 4-year period, not reflecting a long-term treatment [<xref ref-type="bibr" rid="pone.0309160.ref011">11</xref>]. These younger populations receiving more TT have largely not been evaluated in prior research and thus we do not know the long-term efficacy or adverse effects of therapy initiation or cessation earlier in life. It is unclear why larger increases in prevalence were seen in Texas and Arkansas, but could reflect a combination of physician practice, public interest, and regulatory oversight methods.</p>
<p>Even when TT is clearly indicated, the marginal clinical efficacy is reflected in the low adherence rates seen both in clinical trials [<xref ref-type="bibr" rid="pone.0309160.ref003">3</xref>] and real-world studies [<xref ref-type="bibr" rid="pone.0309160.ref020">20</xref>]. Claims of its ability to modify diabetes risk and control have come under question as well [<xref ref-type="bibr" rid="pone.0309160.ref021">21</xref>]. While TT did not show an increased risk of major adverse cardiac events (MACE) in a high-risk population [<xref ref-type="bibr" rid="pone.0309160.ref022">22</xref>], most research has been limited to topical gels and not the more widely used injectable formulations that have shown a higher incidence of MACE, hospitalizations, and death [<xref ref-type="bibr" rid="pone.0309160.ref023">23</xref>]. Emerging evidence suggests that middle-aged and older men treated for hypogonadism with TT showed increased risks of concerning arrhythmias, pulmonary embolism, acute kidney injury, and fractures [<xref ref-type="bibr" rid="pone.0309160.ref003">3</xref>, <xref ref-type="bibr" rid="pone.0309160.ref024">24</xref>], bearing concern for the broader effects on the population from such a sharp uptick in utilization.</p>
<p>Our study’s main strength is the utilization of state PDMP databases with mandatory inclusion of all dispensed prescriptions regardless of payor, in contrast to commercial databases and is the first to report new TT prescribing data since 2018. The weaknesses inherent in the study stem from the databases available—lack of identifying information, diagnoses and testosterone levels preclude further analysis of disease prevalence and appropriateness of care. The databases also do not include testosterone formulations administered in a clinic setting, so our results underrepresent the scope of the observed TT prescribing practices. The regional differences are heavily impacted by the inability to include data from half the country and there is a lack of prior PDMP data in many cases to further compare temporal trends. As our study was unfunded, the lack of access to assistance prohibited more in-depth statistical analysis to augment our findings and we would encourage further research in this area.</p>
</sec>
<sec id="sec014" sec-type="conclusions">
<title>Conclusions</title>
<p>Results of this cross-sectional study show that during the COVID-19 pandemic, US national trends in the prescriptions for TT significantly increased, exceeding pre-pandemic trends, particularly in younger male adults. Additional research is needed to differentiate the increases due to unmet need vs overprescribing, to discern the impact of TT prescribing in the states unable to participate in our analysis, and to understand the impact of TT in the younger male population not included in prior studies. We strongly encourage TT prescribing pattern analysis by the more populous states who noted legislative prohibition from inclusion in our study (NY, FL, CA, NC, MI) as well as comparison of the interstate surveillance and enforcement methods for controlled substances as this could impact some of the observed differences.</p>
</sec>
<sec id="sec015" sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material id="pone.0309160.s001" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" position="float" xlink:href="info:doi/10.1371/journal.pone.0309160.s001" xlink:type="simple">
<label>S1 Data</label>
<caption>
<title/>
<p>(XLSX)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>Acknowledgements for specific data sets.</p>
<p>Kentucky: Research reported in this publication was supported, in part, by the Cabinet for Health and Family Services, Office of Inspector General.</p>
<p>Maryland: Aggregate counts were prepared by the Office of Provider Engagement and Regulation, Maryland Department of Health (MDH): Prescription Drug Monitoring Program. The Maryland PDMP data provided is considered preliminary and subject to change, pending finalization of PDMP data by data owners. MDH is not responsible for data analyses, interpretations, conclusions, or references to PDMP data. Contents are solely the responsibility of the authors and do not necessarily represent the official views of MDH.</p>
<p>Pennsylvania: These data were supplied by the Office of Drug Surveillance and Misuse Prevention, Pennsylvania Department of Health, Harrisburg, Pennsylvania. The Pennsylvania Department of Health specifically disclaims responsibility for any analyses, interpretations, or conclusions.</p>
<p>South Carolina: This information is from the records of the prescription monitoring program, South Carolina Department of Health and Environmental Control. Their authorization to release this information does not imply endorsement of this study or its findings by either the prescription monitoring program or the Department of Health and Environmental Control.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pone.0309160.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Baillargeon</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Kuo</surname> <given-names>YF</given-names></name>, <name name-style="western"><surname>Westra</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Urban</surname> <given-names>RJ</given-names></name>, <name name-style="western"><surname>Goodwin</surname> <given-names>JS</given-names></name>. <article-title>Testosterone Prescribing in the United States, 2002–2016</article-title>. <source>JAMA</source>. <year>2018</year> <month>Jul</month> <day>10</day>;<volume>320</volume>(<issue>2</issue>):<fpage>200</fpage>–<lpage>202</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jama.2018.7999" xlink:type="simple">10.1001/jama.2018.7999</ext-link></comment> <object-id pub-id-type="pmid">29998328</object-id>.</mixed-citation></ref>
<ref id="pone.0309160.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Baillargeon</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Urban</surname> <given-names>RJ</given-names></name>, <name name-style="western"><surname>Ottenbacher</surname> <given-names>KJ</given-names></name>, <name name-style="western"><surname>Pierson</surname> <given-names>KS</given-names></name>, <name name-style="western"><surname>Goodwin</surname> <given-names>JS</given-names></name>. <article-title>Trends in androgen prescribing in the United States, 2001 to 2011</article-title>. <source>JAMA Intern Med</source>. <year>2013</year> <month>Aug</month> <day>12</day>;<volume>173</volume>(<issue>15</issue>):<fpage>1465</fpage>–<lpage>6</lpage>. Erratum in: JAMA Intern Med. 2013 Aug 12;173(15):1477. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jamainternmed.2013.6895" xlink:type="simple">10.1001/jamainternmed.2013.6895</ext-link></comment> <object-id pub-id-type="pmid">23939517</object-id>.</mixed-citation></ref>
<ref id="pone.0309160.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bandari</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Ayyash</surname> <given-names>OM</given-names></name>, <name name-style="western"><surname>Emery</surname> <given-names>SL</given-names></name>, <name name-style="western"><surname>Wessel</surname> <given-names>CB</given-names></name>, <name name-style="western"><surname>Davies</surname> <given-names>BJ</given-names></name>. <article-title>Marketing and Testosterone Treatment in the USA: A Systematic Review</article-title>. <source>Eur Urol Focus</source>. <year>2017</year> <month>Oct</month>;<volume>3</volume>(<issue>4–5</issue>):<fpage>395</fpage>–<lpage>402</lpage>. Epub 2017 Nov 23. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.euf.2017.10.016" xlink:type="simple">10.1016/j.euf.2017.10.016</ext-link></comment> <object-id pub-id-type="pmid">29174614</object-id>.</mixed-citation></ref>
<ref id="pone.0309160.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Selinger</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Ancha</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Frei</surname> <given-names>CR</given-names></name>. <article-title>Testosterone Prescribing in Texas, 2018–2021</article-title>. <source>J Gen Intern Med</source>. <year>2023</year> <month>Nov</month>;<volume>38</volume>(<issue>15</issue>):<fpage>3436</fpage>–<lpage>3438</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s11606-023-08316-y" xlink:type="simple">10.1007/s11606-023-08316-y</ext-link></comment> <object-id pub-id-type="pmid">37436571</object-id>.</mixed-citation></ref>
<ref id="pone.0309160.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Morden</surname> <given-names>NE</given-names></name>, <name name-style="western"><surname>Woloshin</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Brooks</surname> <given-names>CG</given-names></name>, <name name-style="western"><surname>Schwartz</surname> <given-names>LM</given-names></name>. <article-title>Trends in Testosterone Prescribing for Age-related Hypogonadism in Men With and Without Heart Disease</article-title>. <source>JAMA Intern Med</source>. <year>2019</year> <month>Mar</month> <day>1</day>;<volume>179</volume>(<issue>3</issue>):<fpage>446</fpage>–<lpage>448</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jamainternmed.2018.6505" xlink:type="simple">10.1001/jamainternmed.2018.6505</ext-link></comment> <object-id pub-id-type="pmid">30592484</object-id></mixed-citation></ref>
<ref id="pone.0309160.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sellke</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Omil-Lima</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Sun</surname> <given-names>HH</given-names></name>, <name name-style="western"><surname>Tay</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Rhodes</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Loeb</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Trends in testosterone prescription during the release of society guidelines</article-title>. <source>Int J Impot Res</source>. <year>2024</year> <month>Jun</month>;<volume>36</volume>(<issue>4</issue>):<fpage>380</fpage>–<lpage>384</lpage>. Epub 2023 May 2. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41443-023-00709-1" xlink:type="simple">10.1038/s41443-023-00709-1</ext-link></comment> <object-id pub-id-type="pmid">37130972</object-id>.</mixed-citation></ref>
<ref id="pone.0309160.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Auerbach</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Moghalu</surname> <given-names>OI</given-names></name>, <name name-style="western"><surname>Das</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Horns</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Campbell</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Hotaling</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Evaluating incidence, prevalence, and treatment trends in adult men with hypogonadism in the United States</article-title>. <source>Int J Impot Res</source>. <year>2022</year> <month>Dec</month>;<volume>34</volume>(<issue>8</issue>):<fpage>762</fpage>–<lpage>768</lpage>. Epub 2021 Nov 29. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41443-021-00471-2" xlink:type="simple">10.1038/s41443-021-00471-2</ext-link></comment> <object-id pub-id-type="pmid">34845356</object-id>.</mixed-citation></ref>
<ref id="pone.0309160.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Handelsman</surname> <given-names>DJ</given-names></name>. <article-title>Global trends in testosterone prescribing, 2000–2011: expanding the spectrum of prescription drug misuse</article-title>. <source>Med J Aust</source>. <year>2013</year> <month>Oct</month> <day>21</day>;<volume>199</volume>(<issue>8</issue>):<fpage>548</fpage>–<lpage>51</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5694/mja13.10111" xlink:type="simple">10.5694/mja13.10111</ext-link></comment> <object-id pub-id-type="pmid">24138381</object-id>.</mixed-citation></ref>
<ref id="pone.0309160.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Grossmann</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Anawalt</surname> <given-names>BD</given-names></name>, <name name-style="western"><surname>Wu</surname> <given-names>FC</given-names></name>. <article-title>Clinical practice patterns in the assessment and management of low testosterone in men: an international survey of endocrinologists</article-title>. <source>Clin Endocrinol (Oxf)</source>. <year>2015</year> <month>Feb</month>;<volume>82</volume>(<issue>2</issue>):<fpage>234</fpage>–<lpage>41</lpage>. Epub 2014 Sep 24. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/cen.12594" xlink:type="simple">10.1111/cen.12594</ext-link></comment> <object-id pub-id-type="pmid">25154540</object-id>.</mixed-citation></ref>
<ref id="pone.0309160.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jowett</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Shevlin</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Hyland</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Karatzias</surname> <given-names>T</given-names></name>. <article-title>Posttraumatic Stress Disorder and Persistent Somatic Symptoms During the COVID-19 Pandemic: The Role of Sense of Threat</article-title>. <source>Psychosom Med</source>. <year>2021</year> <month>May</month> <day>1</day>;<volume>83</volume>(<issue>4</issue>):<fpage>338</fpage>–<lpage>344</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/PSY.0000000000000890" xlink:type="simple">10.1097/PSY.0000000000000890</ext-link></comment> <object-id pub-id-type="pmid">33818055</object-id>.</mixed-citation></ref>
<ref id="pone.0309160.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hawes</surname> <given-names>MT</given-names></name>, <name name-style="western"><surname>Szenczy</surname> <given-names>AK</given-names></name>, <name name-style="western"><surname>Klein</surname> <given-names>DN</given-names></name>, <name name-style="western"><surname>Hajcak</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Nelson</surname> <given-names>BD</given-names></name>. <article-title>Increases in depression and anxiety symptoms in adolescents and young adults during the COVID-19 pandemic</article-title>. <source>Psychol Med</source>. <year>2021</year> <month>Jan</month> <volume>13</volume>:<fpage>1</fpage>–<lpage>9</lpage>. Epub ahead of print. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1017/S0033291720005358" xlink:type="simple">10.1017/S0033291720005358</ext-link></comment> <object-id pub-id-type="pmid">33436120</object-id>.</mixed-citation></ref>
<ref id="pone.0309160.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bhutani</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>vanDellen</surname> <given-names>MR</given-names></name>, <name name-style="western"><surname>Cooper</surname> <given-names>JA</given-names></name>. <article-title>Longitudinal Weight Gain and Related Risk Behaviors during the COVID-19 Pandemic in Adults in the US</article-title>. <source>Nutrients</source>. <year>2021</year> <month>Feb</month> <day>19</day>;<volume>13</volume>(<issue>2</issue>):<fpage>671</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3390/nu13020671" xlink:type="simple">10.3390/nu13020671</ext-link></comment> <object-id pub-id-type="pmid">33669622</object-id>.</mixed-citation></ref>
<ref id="pone.0309160.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Faust</surname> <given-names>JS</given-names></name>, <name name-style="western"><surname>Du</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Mayes</surname> <given-names>KD</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>SX</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Barnett</surname> <given-names>ML</given-names></name>, <etal>et al</etal>. <article-title>Mortality From Drug Overdoses, Homicides, Unintentional Injuries, Motor Vehicle Crashes, and Suicides During the Pandemic, March-August 2020</article-title>. <source>JAMA</source>. <year>2021</year> <month>Jul</month> <day>6</day>;<volume>326</volume>(<issue>1</issue>):<fpage>84</fpage>–<lpage>86</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jama.2021.8012" xlink:type="simple">10.1001/jama.2021.8012</ext-link></comment> <object-id pub-id-type="pmid">34019096</object-id>.</mixed-citation></ref>
<ref id="pone.0309160.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chai</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Xu</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Goyal</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Trends in Incident Prescriptions for Behavioral Health Medications in the US, 2018–2022</article-title>. <source>JAMA Psychiatry</source>. Published online <month>January</month> <day>10</day>, <year>2024</year>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jamapsychiatry.2023.5045" xlink:type="simple">10.1001/jamapsychiatry.2023.5045</ext-link></comment> <object-id pub-id-type="pmid">38198145</object-id></mixed-citation></ref>
<ref id="pone.0309160.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Milani</surname> <given-names>SA</given-names></name>, <name name-style="western"><surname>Raji</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Kuo</surname> <given-names>YF</given-names></name>. <article-title>Trends in the Use of Benzodiazepines, Z-Hypnotics, and Serotonergic Drugs Among US Women and Men Before and During the COVID-19 Pandemic</article-title>. <source>JAMA Netw Open</source>. <year>2021</year> <month>Oct</month> <day>1</day>;<volume>4</volume>(<issue>10</issue>):<fpage>e2131012</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jamanetworkopen.2021.31012" xlink:type="simple">10.1001/jamanetworkopen.2021.31012</ext-link></comment> <object-id pub-id-type="pmid">34694388</object-id>.</mixed-citation></ref>
<ref id="pone.0309160.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Oliffe</surname> <given-names>JL</given-names></name>, <name name-style="western"><surname>Rossnagel</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Seidler</surname> <given-names>ZE</given-names></name>, <name name-style="western"><surname>Kealy</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Ogrodniczuk</surname> <given-names>JS</given-names></name>, <name name-style="western"><surname>Rice</surname> <given-names>SM</given-names></name>. <article-title>Men’s Depression and Suicide</article-title>. <source>Curr Psychiatry Rep</source>. <year>2019</year> <month>Sep</month> <day>14</day>;<volume>21</volume>(<issue>10</issue>):<fpage>103</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s11920-019-1088-y" xlink:type="simple">10.1007/s11920-019-1088-y</ext-link></comment> <object-id pub-id-type="pmid">31522267</object-id>.</mixed-citation></ref>
<ref id="pone.0309160.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ettman</surname> <given-names>CK</given-names></name>, <name name-style="western"><surname>Cohen</surname> <given-names>GH</given-names></name>, <name name-style="western"><surname>Abdalla</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Sampson</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Trinquart</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Castrucci</surname> <given-names>BC</given-names></name>, <etal>et al</etal>. <article-title>Persistent depressive symptoms during COVID-19: a national, population-representative, longitudinal study of U.S. adults</article-title>. <source>Lancet Reg Health Am</source>. <year>2022</year> <month>Jan</month>;<volume>5</volume>:<fpage>100091</fpage>. Epub 2021 Oct 4. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.lana.2021.100091" xlink:type="simple">10.1016/j.lana.2021.100091</ext-link></comment> <object-id pub-id-type="pmid">34635882</object-id>.</mixed-citation></ref>
<ref id="pone.0309160.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Snyder</surname> <given-names>PJ</given-names></name>, <name name-style="western"><surname>Ellenberg</surname> <given-names>SS</given-names></name>, <name name-style="western"><surname>Cunningham</surname> <given-names>GR</given-names></name>, <name name-style="western"><surname>Matsumoto</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Bhasin</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Barrett-Connor</surname> <given-names>E</given-names></name>, <etal>et al</etal>. <article-title>The Testosterone Trials: Seven coordinated trials of testosterone treatment in elderly men</article-title>. <source>Clin Trials</source>. <year>2014</year> <month>Jun</month>;<volume>11</volume>(<issue>3</issue>):<fpage>362</fpage>–<lpage>375</lpage>. Erratum in: Clin Trials. 2015 Jun;12(3):291. 10.1177/1740774515580059. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1177/1740774514524032" xlink:type="simple">10.1177/1740774514524032</ext-link></comment> <object-id pub-id-type="pmid">24686158</object-id>.</mixed-citation></ref>
<ref id="pone.0309160.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dubin</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Jesse</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Fantus</surname> <given-names>RJ</given-names></name>, <name name-style="western"><surname>Bennett</surname> <given-names>NE</given-names></name>, <name name-style="western"><surname>Brannigan</surname> <given-names>RE</given-names></name>, <name name-style="western"><surname>Thirumavalavan</surname> <given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Guideline-Discordant Care Among Direct-to-Consumer Testosterone Therapy Platforms</article-title>. <source>JAMA Intern Med</source>. <year>2022</year> <month>Dec</month> <day>1</day>;<volume>182</volume>(<issue>12</issue>):<fpage>1321</fpage>–<lpage>1323</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jamainternmed.2022.4928" xlink:type="simple">10.1001/jamainternmed.2022.4928</ext-link></comment> <object-id pub-id-type="pmid">36469030</object-id>.</mixed-citation></ref>
<ref id="pone.0309160.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schoenfeld</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Shortridge</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Cui</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Muram</surname> <given-names>D</given-names></name>. <article-title>Medication adherence and treatment patterns for hypogonadal patients treated with topical testosterone therapy: a retrospective medical claims analysis</article-title>. <source>J Sex Med</source>. <year>2013</year> <month>May</month>;<volume>10</volume>(<issue>5</issue>):<fpage>1401</fpage>–<lpage>9</lpage>. Epub 2013 Mar 6. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/jsm.12114" xlink:type="simple">10.1111/jsm.12114</ext-link></comment> <object-id pub-id-type="pmid">23464534</object-id>.</mixed-citation></ref>
<ref id="pone.0309160.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bhasin</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Lincoff</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Nissen</surname> <given-names>SE</given-names></name>, <etal>et al</etal>. <article-title>Effect of Testosterone on Progression From Prediabetes to Diabetes in Men With Hypogonadism: A Substudy of the TRAVERSE Randomized Clinical Trial</article-title>. <source><italic>JAMA Intern Med</italic></source>. Published online <month>February</month> <volume>05</volume>, <fpage>2024</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jamainternmed.2023.7862" xlink:type="simple">10.1001/jamainternmed.2023.7862</ext-link></comment> <object-id pub-id-type="pmid">38315466</object-id></mixed-citation></ref>
<ref id="pone.0309160.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lincoff</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Bhasin</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Flevaris</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Mitchell</surname> <given-names>LM</given-names></name>, <name name-style="western"><surname>Basaria</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Boden</surname> <given-names>WE</given-names></name>, <etal>et al</etal>. <article-title>Cardiovascular Safety of Testosterone-Replacement Therapy</article-title>. <source>N Engl J Med</source>. <year>2023</year> <month>Jul</month> <day>13</day>;<volume>389</volume>(<issue>2</issue>):<fpage>107</fpage>–<lpage>117</lpage>. Epub 2023 Jun 16. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMoa2215025" xlink:type="simple">10.1056/NEJMoa2215025</ext-link></comment> <object-id pub-id-type="pmid">37326322</object-id>.</mixed-citation></ref>
<ref id="pone.0309160.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Layton</surname> <given-names>JB</given-names></name>, <name name-style="western"><surname>Meier</surname> <given-names>CR</given-names></name>, <name name-style="western"><surname>Sharpless</surname> <given-names>JL</given-names></name>, <name name-style="western"><surname>Stürmer</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Jick</surname> <given-names>SS</given-names></name>, <name name-style="western"><surname>Brookhart</surname> <given-names>MA</given-names></name>. <article-title>Comparative Safety of Testosterone Dosage Forms</article-title>. <source><italic>JAMA Intern Med</italic></source>. <year>2015</year>;<volume>175</volume>(<issue>7</issue>):<fpage>1187</fpage>–<lpage>1196</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jamainternmed.2015.1573" xlink:type="simple">10.1001/jamainternmed.2015.1573</ext-link></comment> <object-id pub-id-type="pmid">25962056</object-id></mixed-citation></ref>
<ref id="pone.0309160.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Snyder</surname> <given-names>PJ</given-names></name>, <name name-style="western"><surname>Bauer</surname> <given-names>DC</given-names></name>, <name name-style="western"><surname>Ellenberg</surname> <given-names>SS</given-names></name>, <name name-style="western"><surname>Cauley</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Buhr</surname> <given-names>KA</given-names></name>, <name name-style="western"><surname>Bhasin</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Testosterone Treatment and Fractures in Men with Hypogonadism</article-title>. <source>N Engl J Med</source>. <year>2024</year> <month>Jan</month> <day>18</day>;<volume>390</volume>(<issue>3</issue>):<fpage>203</fpage>–<lpage>211</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMoa2308836" xlink:type="simple">10.1056/NEJMoa2308836</ext-link></comment> <object-id pub-id-type="pmid">38231621</object-id>.</mixed-citation></ref>
</ref-list>
</back>
<sub-article article-type="author-comment" id="pone.0309160.r001" specific-use="rebutted-decision-letter-unavailable">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pone.0309160.r001</article-id>
<title-group>
<article-title>Author response to previous submission</article-title>
</title-group>
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>0</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p>
<named-content content-type="author-response-date">7 Apr 2024</named-content>
</p>
<supplementary-material id="pone.0309160.s002" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pone.0309160.s002" xlink:type="simple">
<label>Attachment</label>
<caption>
<p>Submitted filename: <named-content content-type="submitted-filename">IRB approval letter.pdf</named-content></p>
</caption>
</supplementary-material>
</body>
</sub-article>
<sub-article article-type="aggregated-review-documents" id="pone.0309160.r002" specific-use="decision-letter">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pone.0309160.r002</article-id>
<title-group>
<article-title>Decision Letter 0</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name name-style="western">
<surname>de Silva</surname>
<given-names>Appuwawadu Mestri Nipun Lakshitha</given-names>
</name>
<role>Academic Editor</role>
</contrib>
</contrib-group>
<permissions>
<copyright-year>2024</copyright-year>
<copyright-holder>Appuwawadu Mestri Nipun Lakshitha de Silva</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<related-object document-id="10.1371/journal.pone.0309160" document-id-type="doi" document-type="article" id="rel-obj002" link-type="peer-reviewed-article"/>
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>0</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p>
<named-content content-type="letter-date">10 Jun 2024</named-content>
</p>
<p><!-- <div> -->PONE-D-24-13515<!-- </div> --><!-- <div> -->Cross-Sectional Analysis of National Testosterone Prescribing through Prescription Drug Monitoring Programs, 2018-2022<!-- </div> --><!-- <div> -->PLOS ONE</p>
<p>Dear Dr. Selinger,</p>
<p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please pay particular attention to following areas. </p>
<p>1. It is essential to clarify whether incidence or prevalence was calculated. <!-- </div> --><!-- <div> -->2. The conclusion should be limited to what can be arrived from the available results. <!-- </div> --><!-- <div> -->3. I would recommend improving the discussion with special emphasis on comparison with global trends during the studied period and trends in the region before the period covered by this study. </p>
<p>Please submit your revised manuscript by Jul 25 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <email xlink:type="simple">plosone@plos.org</email>. When you're ready to submit your revision, log on to <ext-link ext-link-type="uri" xlink:href="https://www.editorialmanager.com/pone/" xlink:type="simple">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p>
<p>Please include the following items when submitting your revised manuscript:<!-- </div> --><list list-type="bullet"><list-item><p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p></list-item><list-item><p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p></list-item><list-item><p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p></list-item></list></p>
<p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p>
<p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols" xlink:type="simple">https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link>. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at <ext-link ext-link-type="uri" xlink:href="https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols" xlink:type="simple">https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols</ext-link>.</p>
<p>We look forward to receiving your revised manuscript.</p>
<p>Kind regards,</p>
<p>Appuwawadu Mestri Nipun Lakshitha de Silva, MBBS, MD</p>
<p>Academic Editor</p>
<p>PLOS ONE</p>
<p>Journal requirements:</p>
<p>When submitting your revision, we need you to address these additional requirements.</p>
<p>1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at</p>
<p><ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf" xlink:type="simple">https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf</ext-link> and</p>
<p><ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf" xlink:type="simple">https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf</ext-link></p>
<p>2. We note that you have indicated that there are restrictions to data sharing for this study. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see <ext-link ext-link-type="uri" xlink:href="http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions" xlink:type="simple">http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions</ext-link>.</p>
<p>Before we proceed with your manuscript, please address the following prompts:</p>
<p>a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., a Research Ethics Committee or Institutional Review Board, etc.). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.</p>
<p>b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see</p>
<p><ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/recommended-repositories" xlink:type="simple">https://journals.plos.org/plosone/s/recommended-repositories</ext-link>. You also have the option of uploading the data as Supporting Information files, but we would recommend depositing data directly to a data repository if possible.</p>
<p>We will update your Data Availability statement on your behalf to reflect the information you provide.</p>
<p>3. We note that Figure 3 in your submission contain [map/satellite] images which may be copyrighted. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For these reasons, we cannot publish previously copyrighted maps or satellite images created using proprietary data, such as Google software (Google Maps, Street View, and Earth). For more information, see our copyright guidelines: <ext-link ext-link-type="uri" xlink:href="http://journals.plos.org/plosone/s/licenses-and-copyright" xlink:type="simple">http://journals.plos.org/plosone/s/licenses-and-copyright</ext-link>.</p>
<p>We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission:</p>
<p>1. You may seek permission from the original copyright holder of Figure(s) [#] to publish the content specifically under the CC BY 4.0 license. </p>
<p>We recommend that you contact the original copyright holder with the Content Permission Form (<ext-link ext-link-type="uri" xlink:href="http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf" xlink:type="simple">http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf</ext-link>) and the following text:</p>
<p>“I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">http://creativecommons.org/licenses/by/4.0/</ext-link>). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.”</p>
<p>Please upload the completed Content Permission Form or other proof of granted permissions as an "Other" file with your submission.</p>
<p>In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].”</p>
<p>2. If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.</p>
<p>The following resources for replacing copyrighted map figures may be helpful:</p>
<p>USGS National Map Viewer (public domain): <ext-link ext-link-type="uri" xlink:href="http://viewer.nationalmap.gov/viewer/" xlink:type="simple">http://viewer.nationalmap.gov/viewer/</ext-link></p>
<p>The Gateway to Astronaut Photography of Earth (public domain): <ext-link ext-link-type="uri" xlink:href="http://eol.jsc.nasa.gov/sseop/clickmap/" xlink:type="simple">http://eol.jsc.nasa.gov/sseop/clickmap/</ext-link></p>
<p>Maps at the CIA (public domain): <ext-link ext-link-type="uri" xlink:href="https://www.cia.gov/library/publications/the-world-factbook/index.html" xlink:type="simple">https://www.cia.gov/library/publications/the-world-factbook/index.html</ext-link> and <ext-link ext-link-type="uri" xlink:href="https://www.cia.gov/library/publications/cia-maps-publications/index.html" xlink:type="simple">https://www.cia.gov/library/publications/cia-maps-publications/index.html</ext-link></p>
<p>NASA Earth Observatory (public domain): <ext-link ext-link-type="uri" xlink:href="http://earthobservatory.nasa.gov/" xlink:type="simple">http://earthobservatory.nasa.gov/</ext-link></p>
<p>Landsat: <ext-link ext-link-type="uri" xlink:href="http://landsat.visibleearth.nasa.gov/" xlink:type="simple">http://landsat.visibleearth.nasa.gov/</ext-link></p>
<p>USGS EROS (Earth Resources Observatory and Science (EROS) Center) (public domain): <ext-link ext-link-type="uri" xlink:href="http://eros.usgs.gov/#" xlink:type="simple">http://eros.usgs.gov/#</ext-link></p>
<p>Natural Earth (public domain): <ext-link ext-link-type="uri" xlink:href="http://www.naturalearthdata.com/" xlink:type="simple">http://www.naturalearthdata.com/</ext-link></p>
<p>4. Please include a separate caption for each figure in your manuscript.</p>
<p>5. Please include your tables as part of your main manuscript and remove the individual files. Please note that supplementary tables (should remain/ be uploaded) as separate "supporting information" files.</p>
<p>6. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: <ext-link ext-link-type="uri" xlink:href="http://journals.plos.org/plosone/s/supporting-information" xlink:type="simple">http://journals.plos.org/plosone/s/supporting-information</ext-link>.</p>
<p>[Note: HTML markup is below. Please do not edit.]</p>
<p>Reviewers' comments:</p>
<p>Reviewer's Responses to Questions</p>
<p><!-- <font color="black"> --><bold>Comments to the Author</bold></p>
<p>1. Is the manuscript technically sound, and do the data support the conclusions?</p>
<p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. <!-- </font> --></p>
<p>Reviewer #1: Partly</p>
<p>Reviewer #2: Partly</p>
<p>**********</p>
<p><!-- <font color="black"> -->2. Has the statistical analysis been performed appropriately and rigorously? <!-- </font> --></p>
<p>Reviewer #1: N/A</p>
<p>Reviewer #2: I Don't Know</p>
<p>**********</p>
<p><!-- <font color="black"> -->3. Have the authors made all data underlying the findings in their manuscript fully available?</p>
<p>The <ext-link ext-link-type="uri" xlink:href="http://www.plosone.org/static/policies.action#sharing" xlink:type="simple">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.<!-- </font> --></p>
<p>Reviewer #1: No</p>
<p>Reviewer #2: No</p>
<p>**********</p>
<p><!-- <font color="black"> -->4. Is the manuscript presented in an intelligible fashion and written in standard English?</p>
<p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.<!-- </font> --></p>
<p>Reviewer #1: Yes</p>
<p>Reviewer #2: Yes</p>
<p>**********</p>
<p><!-- <font color="black"> -->5. Review Comments to the Author</p>
<p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)<!-- </font> --></p>
<p>Reviewer #1: In my opinion, the rationale of this kind of analysis is not very clear. The increase of testosterone use can be concerning and may deserve to be monitored, but the overall prevalence is quite low (also in 2022), with the exception of subjects &gt;=45 years old.</p>
<p>Some comments and suggestions:</p>
<p>1. The study is mainly descriptive. In my opinion, a few statistical analyses (e.g. chi-square for trend; chi square test to compare prevalence by gender) may be helpful.</p>
<p>2. In the methods section you stated that incident rates were calculated, and data were reported in Table 1 and figure 4. This means that it was possible to estimate the number of new TT users? It seems likely to me that subjects reported in table 1 are prevalent, and not incident, cases.</p>
<p>3. I would like to suggest to better clarify how the expected incidence (prevalence?) in 2021-2022 was estimated, and what the values reported in figure 3 represents (what does 1.8% stand for?).</p>
<p>4. It is not very clear to me what is your hypothesis for the increease in TT users during the pandemic period. A mis-diagnosis of hyopogonadism, due to an increase in symptoms associated to a decrease in mental well-being?</p>
<p>5. Geographical differences in the prevalence of TT prescription were observed, but not discussed.</p>
<p>Moreover, it seems to me that the greater than expected rise in users in the 2021-2022 period was limited to very few states (mainly Texas and Arkansas).</p>
<p>Have you any hypothesis about the reasons of these differences?</p>
<p>6. Abstract - results section: The sentence "The number of people treated annually with TT increased 439,659, a 27% rise with 80% of this increase during..." is not very clear. Maybe it could be changed in "In 2022 there was a 27% relative increase of subjects treated with TT (+439,659 cases compared with 2018). The increase was more evident in the pandemic period, with a rise in the prevalence from ... to ..."</p>
<p>Reviewer #2: The authors present a evaluation on the trends in testosterone prescription use in the US. As previously seen, the overall trend is upward with more prescriptions being written/filled. The underlying reasons for this are not investigated by the methodology. I therefore caution the authors on the conclusions presented in the abstract and discussion that any specific link to COVID-19, mental health, or marketing practices. The link to the pandemic should be presented less strongly as the number of confounders is unknown and the methodology do not address or assess this link. For example the trend is going upward throughout the study period and the last two years happen to be during the pandemic.</p>
<p>**********</p>
<p><!-- <font color="black"> -->6. PLOS authors have the option to publish the peer review history of their article (<ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" xlink:type="simple">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
<p>If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
<p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link ext-link-type="uri" xlink:href="https://www.plos.org/privacy-policy" xlink:type="simple">Privacy Policy</ext-link>.<!-- </font> --></p>
<p>Reviewer #1: No</p>
<p>Reviewer #2: No</p>
<p>**********</p>
<p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p>
<p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <ext-link ext-link-type="uri" xlink:href="https://pacev2.apexcovantage.com/" xlink:type="simple">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <email xlink:type="simple">figures@plos.org</email>. Please note that Supporting Information files do not need this step.</p>
</body>
</sub-article>
<sub-article article-type="author-comment" id="pone.0309160.r003">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pone.0309160.r003</article-id>
<title-group>
<article-title>Author response to Decision Letter 0</article-title>
</title-group>
<related-object document-id="10.1371/journal.pone.0309160" document-id-type="doi" document-type="peer-reviewed-article" id="rel-obj003" link-type="rebutted-decision-letter" object-id="10.1371/journal.pone.0309160.r002" object-id-type="doi" object-type="decision-letter"/>
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>1</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p>
<named-content content-type="author-response-date">11 Jul 2024</named-content>
</p>
<p>I believe I have answered all questions and comments sent back in the revision and attached response to reviewers as well as updated the manuscript to conform to the journals formatting requirements</p>
<supplementary-material id="pone.0309160.s003" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pone.0309160.s003" xlink:type="simple">
<label>Attachment</label>
<caption>
<p>Submitted filename: <named-content content-type="submitted-filename">IRB approval letter.pdf</named-content></p>
</caption>
</supplementary-material>
</body>
</sub-article>
<sub-article article-type="aggregated-review-documents" id="pone.0309160.r004" specific-use="decision-letter">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pone.0309160.r004</article-id>
<title-group>
<article-title>Decision Letter 1</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name name-style="western">
<surname>de Silva</surname>
<given-names>Appuwawadu Mestri Nipun Lakshitha</given-names>
</name>
<role>Academic Editor</role>
</contrib>
</contrib-group>
<permissions>
<copyright-year>2024</copyright-year>
<copyright-holder>Appuwawadu Mestri Nipun Lakshitha de Silva</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<related-object document-id="10.1371/journal.pone.0309160" document-id-type="doi" document-type="article" id="rel-obj004" link-type="peer-reviewed-article"/>
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>1</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p>
<named-content content-type="letter-date">30 Jul 2024</named-content>
</p>
<p><!-- <div> -->PONE-D-24-13515R1<!-- </div> --><!-- <div> -->Cross-Sectional Analysis of National Testosterone Prescribing through Prescription Drug Monitoring Programs, 2018-2022<!-- </div> --><!-- <div> -->PLOS ONE</p>
<p>Dear Dr. Selinger,</p>
<p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p>
<p>Please clarify whether Figure 4 reports incidence rather than prevalence and report the how the incidence was reported in the methods section. </p>
<p>Please submit your revised manuscript by Sep 13 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <email xlink:type="simple">plosone@plos.org</email>. When you're ready to submit your revision, log on to <ext-link ext-link-type="uri" xlink:href="https://www.editorialmanager.com/pone/" xlink:type="simple">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p>
<p>Please include the following items when submitting your revised manuscript:<!-- </div> --><list list-type="bullet"><list-item><p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p></list-item><list-item><p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p></list-item><list-item><p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p></list-item></list><!-- <div> -->If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p>
<p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols" xlink:type="simple">https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link>. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at <ext-link ext-link-type="uri" xlink:href="https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols" xlink:type="simple">https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols</ext-link>.</p>
<p>We look forward to receiving your revised manuscript.</p>
<p>Kind regards,</p>
<p>Appuwawadu Mestri Nipun Lakshitha de Silva, MBBS, MD</p>
<p>Academic Editor</p>
<p>PLOS ONE</p>
<p>Journal Requirements:</p>
<p>Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.</p>
<p>[Note: HTML markup is below. Please do not edit.]</p>
<p>Reviewers' comments:</p>
<p>Reviewer's Responses to Questions</p>
<p><!-- <font color="black"> --><bold>Comments to the Author</bold></p>
<p>1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.<!-- </font> --></p>
<p>Reviewer #1: (No Response)</p>
<p>**********</p>
<p><!-- <font color="black"> -->2. Is the manuscript technically sound, and do the data support the conclusions?</p>
<p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. <!-- </font> --></p>
<p>Reviewer #1: Yes</p>
<p>**********</p>
<p><!-- <font color="black"> -->3. Has the statistical analysis been performed appropriately and rigorously? <!-- </font> --></p>
<p>Reviewer #1: N/A</p>
<p>**********</p>
<p><!-- <font color="black"> -->4. Have the authors made all data underlying the findings in their manuscript fully available?</p>
<p>The <ext-link ext-link-type="uri" xlink:href="http://www.plosone.org/static/policies.action#sharing" xlink:type="simple">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.<!-- </font> --></p>
<p>Reviewer #1: No</p>
<p>**********</p>
<p><!-- <font color="black"> -->5. Is the manuscript presented in an intelligible fashion and written in standard English?</p>
<p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.<!-- </font> --></p>
<p>Reviewer #1: Yes</p>
<p>**********</p>
<p><!-- <font color="black"> -->6. Review Comments to the Author</p>
<p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)<!-- </font> --></p>
<p>Reviewer #1: It seems to me that most of the reviewers' comments and suggestions have been addressed in a satisfactory manner. I still have a revision to suggest:</p>
<p>I'm still not very convinced that in Figure 4 it is reported incidence. The values seems very similar to that reported in table 3 (total column). This means that almost all TT users were "new users"? In any case, I would like to suggest to better explain in the methods section (line 87, page 11) how incident users were defined (subjects with a TT claim in a year and with no TT claims in the previous one?)</p>
<p>**********</p>
<p><!-- <font color="black"> -->7. PLOS authors have the option to publish the peer review history of their article (<ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" xlink:type="simple">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
<p>If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
<p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link ext-link-type="uri" xlink:href="https://www.plos.org/privacy-policy" xlink:type="simple">Privacy Policy</ext-link>.<!-- </font> --></p>
<p>Reviewer #1: No</p>
<p>**********</p>
<p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p>
<p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <ext-link ext-link-type="uri" xlink:href="https://pacev2.apexcovantage.com/" xlink:type="simple">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <email xlink:type="simple">figures@plos.org</email>. Please note that Supporting Information files do not need this step.</p>
</body>
</sub-article>
<sub-article article-type="author-comment" id="pone.0309160.r005">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pone.0309160.r005</article-id>
<title-group>
<article-title>Author response to Decision Letter 1</article-title>
</title-group>
<related-object document-id="10.1371/journal.pone.0309160" document-id-type="doi" document-type="peer-reviewed-article" id="rel-obj005" link-type="rebutted-decision-letter" object-id="10.1371/journal.pone.0309160.r004" object-id-type="doi" object-type="decision-letter"/>
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>2</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p>
<named-content content-type="author-response-date">30 Jul 2024</named-content>
</p>
<p>Please see my attached letter responding to the comment from reviewer #1</p>
<supplementary-material id="pone.0309160.s004" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0309160.s004" xlink:type="simple">
<label>Attachment</label>
<caption>
<p>Submitted filename: <named-content content-type="submitted-filename">Response to Reviewers.docx</named-content></p>
</caption>
</supplementary-material>
</body>
</sub-article>
<sub-article article-type="editor-report" id="pone.0309160.r006" specific-use="decision-letter">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pone.0309160.r006</article-id>
<title-group>
<article-title>Decision Letter 2</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name name-style="western">
<surname>de Silva</surname>
<given-names>Appuwawadu Mestri Nipun Lakshitha</given-names>
</name>
<role>Academic Editor</role>
</contrib>
</contrib-group>
<permissions>
<copyright-year>2024</copyright-year>
<copyright-holder>Appuwawadu Mestri Nipun Lakshitha de Silva</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<related-object document-id="10.1371/journal.pone.0309160" document-id-type="doi" document-type="article" id="rel-obj006" link-type="peer-reviewed-article"/>
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>2</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p>
<named-content content-type="letter-date">7 Aug 2024</named-content>
</p>
<p>Cross-Sectional Analysis of National Testosterone Prescribing through Prescription Drug Monitoring Programs, 2018-2022</p>
<p>PONE-D-24-13515R2</p>
<p>Dear Dr. Selinger,</p>
<p>We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.</p>
<p>Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.</p>
<p>An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at <ext-link ext-link-type="uri" xlink:href="https://www.editorialmanager.com/pone/" xlink:type="simple">Editorial Manager®</ext-link> and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at <email xlink:type="simple">authorbilling@plos.org</email>.</p>
<p>If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <email xlink:type="simple">onepress@plos.org</email>.</p>
<p>Kind regards,</p>
<p>Appuwawadu Mestri Nipun Lakshitha de Silva, MBBS, MD</p>
<p>Academic Editor</p>
<p>PLOS ONE</p>
<p>Additional Editor Comments (optional):</p>
<p>Reviewers' comments:</p>
</body>
</sub-article>
<sub-article article-type="editor-report" id="pone.0309160.r007" specific-use="acceptance-letter">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pone.0309160.r007</article-id>
<title-group>
<article-title>Acceptance letter</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name name-style="western">
<surname>de Silva</surname>
<given-names>Appuwawadu Mestri Nipun Lakshitha</given-names>
</name>
<role>Academic Editor</role>
</contrib>
</contrib-group>
<permissions>
<copyright-year>2024</copyright-year>
<copyright-holder>Appuwawadu Mestri Nipun Lakshitha de Silva</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<related-object document-id="10.1371/journal.pone.0309160" document-id-type="doi" document-type="article" id="rel-obj007" link-type="peer-reviewed-article"/>
</front-stub>
<body>
<p>
<named-content content-type="letter-date">16 Aug 2024</named-content>
</p>
<p>PONE-D-24-13515R2 </p>
<p>PLOS ONE</p>
<p>Dear Dr.  Selinger, </p>
<p>I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.</p>
<p>At this stage, our production department will prepare your paper for publication. This includes ensuring the following:</p>
<p>* All references, tables, and figures are properly cited</p>
<p>* All relevant supporting information is included in the manuscript submission,</p>
<p>* There are no issues that prevent the paper from being properly typeset</p>
<p>If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps. </p>
<p>Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <email xlink:type="simple">onepress@plos.org</email>.</p>
<p>If we can help with anything else, please email us at <email xlink:type="simple">customercare@plos.org</email>.</p>
<p>Thank you for submitting your work to PLOS ONE and supporting open access. </p>
<p>Kind regards, </p>
<p>PLOS ONE Editorial Office Staff</p>
<p>on behalf of</p>
<p>Dr. Appuwawadu Mestri Nipun Lakshitha de Silva </p>
<p>Academic Editor</p>
<p>PLOS ONE</p>
</body>
</sub-article>
</article>